Resistant Starch Has No Effect on Appetite and Food Intake in Individuals with Prediabetes.

Citation metadata

Publisher: Elsevier Science Publishers
Document Type: Clinical report
Length: 571 words

Document controls

Main content

Abstract :

Keywords Type 2 resistant starch; Prediabetes; Food intake; Appetite; Gut hormones Abstract Background Type 2 resistant starch (RS2) has been shown to improve metabolic health outcomes and may increase satiety and suppress appetite and food intake in humans. Objective This study assessed whether 12 weeks of daily RS2 supplementation could influence appetite perception, food intake, and appetite-related gut hormones in adults with prediabetes, relative to the control (CTL) group. Design The study was a randomized controlled trial and analysis of secondary study end points. Participants/setting Sixty-eight adults (body mass index [greater than or equal to]27) aged 35 to 75 years with prediabetes were enrolled in the study at Pennington Biomedical Research Center (2012 to 2016). Fifty-nine subjects were included in the analysis. Intervention Participants were randomized to consume 45 g/day of high-amylose maize (RS2) or an isocaloric amount of the rapidly digestible starch amylopectin (CTL) for 12 weeks. Main outcome measures Subjective appetite measures were assessed via visual analogue scale and the Eating Inventory; appetite-related gut hormones (glucagon-like peptide 1, peptide YY, and ghrelin) were measured during a standard mixed-meal test; and energy and macronutrient intake were assessed by a laboratory food intake (buffet) test, the Remote Food Photography Method, and SmartIntake app. Statistical analyses performed Data were analyzed using linear mixed models, adjusting for treatment group and time as fixed effects, with a significance level of [alpha]=.05. Results RS2 had no effect on subjective measures of appetite, as assessed by visual analogue scale (P 0.05) and the Eating Inventory (P[greater than or equal to]0.24), relative to the CTL group. There were no effects of RS2 supplementation on appetite-related gut hormones, including glucagon-like peptide 1 (P=0.61), peptide YY (P=0.34), and both total (P=0.26) and active (P=0.47) ghrelin compared with the CTL. RS2 had no effect on total energy (P=0.30), carbohydrate (P=0.11), protein (P=0.64), or fat (P=0.37) consumption in response to a buffet meal test, relative to the CTL. In addition, total energy (P=0.40), carbohydrate (P=0.15), protein (P=0.46), and fat (P=0.53) intake, as quantified by the Remote Food Photography Method, were also unaffected by RS2, relative to the CTL. Conclusions RS2 supplementation did not increase satiety or reduce appetite and food intake in adults with prediabetes. * Address correspondence to: Ursula White, PhD, Pennington Biomedical Research Center, 6400 Perkins Rd, Baton Rouge, LA 70808. Article History: Received 21 August 2019; Accepted 24 January 2020 (footnote) STATEMENT OF POTENTIAL CONFLICT OF INTEREST Louisiana State University and Pennington Biomedical Research Center have an interest in the intellectual property surrounding the SmartIntake app and Remote Food Photography Method, and Corby K. Martin is an inventor of the technology. No potential conflict of interest was reported by the remaining authors. (footnote) FUNDING/SUPPORT This trial was funded by a National Institute of Diabetes and Digestive and Kidney Diseases grant (R01DK092575 to E. Ravussin). This work was also supported by a National Institute of Diabetes and Digestive and Kidney Diseases grant (R03DK112006 to U. White); a career development grant from the National Center for Advancing Translational Sciences (KL2TR001419 to C. M. Peterson); a Nutrition Obesity Research Center grant (P30DK072476); and a Louisiana Clinical and Translational Science Center grant (U54GM104940 in part to R. A. Beyl). The sponsors had no role in the design, conduct, analysis, or reporting of the trial. (footnote) This study was registered at, NCT01708694. Byline: Ursula White, PhD [] (*), Courtney M. Peterson, PhD, Robbie A. Beyl, PhD, Corby K. Martin, PhD, Eric Ravussin, PhD

Source Citation

Source Citation   

Gale Document Number: GALE|A662209356